PhRMA Launches National Campaign to Increase Diversity in Clinical Trials

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-04-02-2014
Volume 10
Issue 4

The I'm In campaign is designed to increase participation by diverse patient populations for clinical trials.

The Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Minority Quality Forum have developed a national campaign to help increase diversity in clinical trials.

The I’m In campaign will raise awareness about the importance of clinical research and increase participation by diverse patient populations to help researchers develop potential new medicines. Partnerships with patient advocacy organizations, provider groups, individual physicians, clinical trials sponsors, and researchers will help to drive campaign awareness and involvement.

According to FDA, African Americans represent 12% of the US population but only 5% of clinical trial participants and Hispanics make up 16% of the population but only 1% of clinical trial participants. Inclusion of individuals of varied races, ethnicities, ages, gender, and sexual orientation in clinical trials can help to prevent disparities in the evaluation of potential new medicines.

I’m In will support the National Minority Quality Forum’s Clinical Trial Engagement Network, a solution to help accelerate the inclusion of underrepresented populations in clinical trials. Authorized users will be able to identify potential clinical trial participants by using zip code level mapping of disease clusters and simultaneously identifying and connecting points of care and community resources that can assist with site selection and patient recruitment.

Source: Pharmaceutical Research and Manufacturers of America

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content